CTNM
Price:
$3.92
Market Cap:
$101.42M
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was...[Read more]
Industry
Biotechnology
IPO Date
Stock Exchange
NASDAQ
Ticker
CTNM
According to Contineum Therapeutics, Inc. Class A Common Stock’s latest financial reports and current stock price. The company's current ROE is -24.59%. This represents a change of 292.93% compared to the average of -6.26% of the last 4 quarters.
The mean historical ROE of Contineum Therapeutics, Inc. Class A Common Stock over the last ten years is 3.04%. The current -24.59% ROE has changed -909.69% with respect to the historical average. Over the past ten years (40 quarters), CTNM's ROE was at its highest in in the December 2023 quarter at 11.44%. The ROE was at its lowest in in the March 2023 quarter at -12.28%.
Average
3.04%
Median
2.34%
Minimum
-33.44%
Maximum
40.91%
Discovering the peaks and valleys of Contineum Therapeutics, Inc. Class A Common Stock ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual ROE = 40.91%
Minimum Annual Increase = -228.53%
Minimum Annual ROE = -33.44%
Year | ROE | Change |
---|---|---|
2024 | -21.34% | -36.20% |
2023 | -33.44% | -228.53% |
2022 | 26.02% | -36.40% |
The current ROE of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-9.59%
5-year avg
3.04%
10-year avg
3.04%
Contineum Therapeutics, Inc. Class A Common Stock’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Contineum Therapeutics, Inc. Class A Common Stock using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Contineum Therapeutics, Inc. Class A Common Stock or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Contineum Therapeutics, Inc. Class A Common Stock's ROE?
How is the ROE calculated for Contineum Therapeutics, Inc. Class A Common Stock (CTNM)?
What is the highest ROE for Contineum Therapeutics, Inc. Class A Common Stock (CTNM)?
What is the 3-year average ROE for Contineum Therapeutics, Inc. Class A Common Stock (CTNM)?
What is the 5-year average ROE for Contineum Therapeutics, Inc. Class A Common Stock (CTNM)?
How does the current ROE for Contineum Therapeutics, Inc. Class A Common Stock (CTNM) compare to its historical average?